The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Steroid Injections for Lateral Epicondylalgia Worse than Placebo in Long Term

Steroid Injections for Lateral Epicondylalgia Worse than Placebo in Long Term

May 3, 2013 • By Jeffrey A. Sparks, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Lateral epicondylalgia can be frustrating for both the patient and physician. Conflicting evidence exists for the roles of physical therapy (PT) and corticosteroid injection in lateral epicondylalgia.1-2 Anecdotally, the rheumatology division here at Brigham and Women’s Hospital has noted worse outcomes, such as recurrence and persistent pain, in patients who received corticosteroid injections. However, the evidence to support opinions on PT and corticosteroid injections has been lacking.

You Might Also Like
  • Effectiveness of Steroid Injections vs. Placebo Evaluated for Knee Pain
  • Study Urges Caution with Steroid Injections for Hip Osteoarthritis
  • Use Epidural Steroid Injections Cautiously in Patients with Fracture Risk

Researchers in Australia, led by Brooke Coombes, PhD, explored outcomes in patients with chronic unilateral lateral epicondylalgia in a study recently published in the Journal of the American Medical Association.3 This randomized controlled trial used a 2×2 factorial design so that the 165 participants were randomized to receive either placebo (consisting of normal saline) or corticosteroid injection and also randomized to receive either PT or no PT. The injection arm of the trial was double blinded, while the PT was open label. The primary outcomes were measures of recovery and recurrence assessed at one year. Secondary outcomes were measures of function assessed at 4, 26, and 52 weeks.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The study had impressive follow-up, with 98% of participants completing the one-year study. For the primary outcome, participants who received placebo had a much lower risk of recurrence compared to corticosteroid injection at one year; the result was statistically significant (relative risk 0.23, 99% confidence interval 0.10–0.51). For those who were randomized to receive either PT or no PT, there was no statistical difference in rates of recurrence at one year.

In secondary analyses for the injection arms of the study, those who received a corticosteroid injection and no PT had slightly better functional status at four weeks, but this result reverses at 26 weeks when those who received placebo injection fared better than corticosteroid injection. For functional status, subjects who received placebo or corticosteroid injections fared similarly at one year. For PT, there was a slight, but statistically significant improvement in those patients who received placebo injection at four weeks, but measures of function were similar in the PT vs. no PT groups at 26 and 52 weeks.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

There were few adverse events in the study, mostly consisting of skin depigmentation and atrophy in those who received corticosteroid injections. Overall, participants in this study did well, with 90% reporting much improvement in lateral epicondylalgia symptoms.

The authors conclude that for unilateral lateral epicondylalgia, corticosteroid injection resulted in worse clinical outcomes compared to placebo injection and that there were no significant differences in those who received PT or no PT.

Pages: 1 2 | Single Page

Filed Under: Research Reviews Tagged With: corticosteroid injection, Lateral Epicondylalgia, steroid injection

You Might Also Like:
  • Effectiveness of Steroid Injections vs. Placebo Evaluated for Knee Pain
  • Study Urges Caution with Steroid Injections for Hip Osteoarthritis
  • Use Epidural Steroid Injections Cautiously in Patients with Fracture Risk
  • Placebo Outperforms Glucosamine/Chondroitin Sulfate for Knee OA

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.